Changes to the Code
H.R. 10336 · Dietary Supplement Innovation Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 331 Prohibited acts
1 change the bill asks for here, 1 carried out
- Carried out:
Section 301(ll) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(ll)) is amended to read as follows:
(ll) The introduction or delivery for introduction into interstate commerce of any food (including a dietary supplement) to which has been added a drug approved under section 505 of this Act, a biological product licensed under section 351 of the Public Health Service Act, or a …
§ 331(kk)–(nn)
Start of § 331 to (jj)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (kk) | (kk) | (kk) | ||
| The dissemination of a television advertisement without complying with section 353c 2 of this title. | The dissemination of a television advertisement without complying with section 353c 2 of this title. | |||
| (ll) | (ll) | (ll) | ||
| The introduction or delivery for introduction into interstate commerce of any food to which has been added a drug approved under section | The introduction or delivery for introduction into interstate commerce of any food [inserted: (including a dietary supplement) ]to which has been added a drug approved under section [inserted: 505] of this [inserted: Act], a biological product licensed under section [inserted: 351] of [inserted: the] [inserted: Public Health Service Act], or a drug or biological product for which [inserted: Phase] [inserted: 2 or Phase 3 (as such terms are described in section 312.21(b) of title 21, Code of Federal Regulations (or successor regulations)) ]clinical investigations have been instituted and for which the existence of such investigations has been made public, unless— | |||
| (ll)(1) | (1) | (1) | ||
| [inserted: the drug or biological product was marketed in the United States before October 15, 1994, as or in—] | ||||
| (ll)(1)(A) | (A) [inserted: ] | |||
| [inserted: food; or] | ||||
| (ll)(1)(B) | (B) [inserted: ] | |||
| [inserted: a product that, if the definition of the term “dietary supplement” under section 201(ff) had been in effect at the date of marketing, would have met such definition (other than the labeling requirement in section 201(ff)(2)(C));] | ||||
| (ll)(1) | ||||
| (ll)(2) | (2) | (2) | ||
| [inserted: such drug or biological product was marketed as food or in a dietary supplement before—] | ||||
| (ll)(2)(A) | (A) [inserted: ] | |||
| [inserted: any approval of the drug under section 505;] | ||||
| (ll)(2)(B) | (B) [inserted: ] | |||
| [inserted: any licensure of the biological product under such section 351; or] | ||||
| (ll)(2)(C) | (C) [inserted: ] | |||
| [inserted: any Phase 2 or Phase 3 clinical investigation involving the use of the substance as a drug or biological product has been instituted and the existence of such investigation has been made public;] | ||||
| (ll)(2) | ||||
| (ll)(3) | (3) | (3) | ||
| [inserted: each Phase 2 or Phase 3 clinical investigation referred to in the matter preceding subparagraph (1) has been on inactive status, withdrawn, or both for a continuous period of at least seven years preceding the addition of the drug or biological product in food (including a dietary supplement), or the sponsor has publicly announced discontinuation of drug development activities;] | ||||
| (ll)(3)(A) | (A) | |||
| (ll)(3)(B) | (B) | |||
| (ll)(3)(C) | (C) | |||
| (ll)(3)(D) | (D) | |||
| (ll)(3)(E) | (E) | |||
| (ll)(4) | (4) | (4) | ||
| the drug is a new animal drug whose use is not unsafe under section | the drug is a new animal drug whose use is not unsafe under section [inserted: 512;] | |||
| (ll)(5) | (5) [inserted: ] | |||
| [inserted: the use of the drug or the biological product in the food (including a dietary supplement) is to enhance the safety of the food to which the drug or the biological product is added or applied and not to have independent biological or therapeutic effects on humans, and the use is in conformity with—] | ||||
| (ll)(5)(A) | (A) [inserted: ] | |||
| [inserted: a regulation issued under section 409 prescribing conditions of safe use in food;] | ||||
| (ll)(5)(B) | (B) [inserted: ] | |||
| [inserted: a regulation listing or affirming conditions under which the use of the drug or biological product in food is generally recognized as safe;] | ||||
| (ll)(5)(C) | (C) [inserted: ] | |||
| [inserted: the conditions of use identified in a notification to the Secretary of a claim of exemption from the premarket approval requirements for food additives based on the notifier's determination that the use of the drug or biological product in food is generally recognized as safe, provided that the Secretary has not questioned the general recognition of safety determination in a letter to the notifier; or] | ||||
| (ll)(5)(D) | (D) [inserted: ] | |||
| [inserted: a food contact substance notification that is effective under section 409(h);] | ||||
| (ll)(6) | (6) [inserted: ] | |||
| [inserted: such drug or biological product had been marketed for smoking cessation prior to the date of the enactment of the Food and Drug Administration Amendments Act of 2007; or] | ||||
| (ll)(7) | (7) [inserted: ] | |||
| [inserted: the Secretary, in the Secretary's discretion, has issued an administrative order through a proceeding initiated by the Secretary approving the use of such drug or biological product in food (including a dietary supplement).] | ||||
| (mm) | (mm) | (mm) | ||
| The failure to submit a report or provide a notification required under section 350f(d) of this title. | The failure to submit a report or provide a notification required under section 350f(d) of this title. | |||
| (nn) | (nn) | (nn) | ||
| The falsification of a report or notification required under section 350f(d) of this title. | The falsification of a report or notification required under section 350f(d) of this title. | |||
Rest of § 331 unchanged
21 U.S.C. § 321 Definitions; generally
The bill's words for this section
- Not carried out:
in subparagraph (1)(F), by adding
and
at the end;The bill points to subparagraph (1) of § 321(ff), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (1) in /us/usc/t21/s321/ff - Not carried out:
in subparagraph (2)(C), by striking
; and
at the end and inserting a period; andThe bill points to subparagraph (2) of § 321(ff), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (2) in /us/usc/t21/s321/ff - Not carried out:
by striking
(3) does—
and all that follows throughwould be lawful under this Act.
.“(3) does—” isn't in § 321(ff) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(3) does—” not found in /us/usc/t21/s321/ff